NeoGenomics Inc. Common Stock (NEO)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach NeoGenomics as a Graham-style analyst: show me durable earnings and a margin of safety. The company operates cancer-focused testing laboratories, serving hospitals, oncologists, and pharma. Revenue has grown: in fiscal 2025, the year ended 2025-12-31, revenue was $727.3 million, up from $660.6 million in fiscal 2024 and $591.6 million in fiscal 2023. But the bottom line has been poor: fiscal 2025 net loss was $108.0 million, fiscal 2024 net loss was $78.7 million, and fiscal 2023 net loss was $88.0 million. The latest data offer a hopeful turn: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $201.7 million and net income was $2.2 million, a 1.11% margin; in fiscal Q2 2025, net loss was $45.1 million. Still, fiscal Q1 2026 had a $17.1 million net loss, so one profitable quarter does not prove a trend. At the 2026-10-13 close of $16.66, FairStock calculations show a negative P/E of -42.72, P/B of 2.71, ROE of -6.33%, ROCE of -1.89%, and an EV/EBITDA of 181.13. Free cash flow is negative at -$7.4 million TTM. Debt-to-equity is 0.57. Piotroski 7/9 and Altman 2.17 suggest some accounting improvement but not fortress strength. FairStock's Lynch category is none: losses in each of the last four years mean no category fits. I see a business with top-line momentum but no proven moat or consistent profit. The price already discounts a successful turnaround.

In plain English: NeoGenomics runs cancer-testing laboratories and sells tests to hospitals, doctors, and drug companies. Sales are growing, but the company has lost money for years and only just posted a small profit in the latest quarter. At $16.66, the price looks expensive compared with current profits and cash flow, even though it is below its 52-week high.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer